{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:08:48Z","timestamp":1792595328337,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002076","name":"Emergency Medicine Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002582","name":"American Geriatrics Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002582","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annemergmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Emergency Medicine"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.annemergmed.2024.12.002","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T16:15:40Z","timestamp":1737130540000},"page":"526-536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Anti-Amyloid Therapies for Alzheimer\u2019s Disease and Amyloid-Related Imaging Abnormalities: Implications for the Emergency Medicine Clinician"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6542-518X","authenticated-orcid":false,"given":"Megan A.","family":"Rech","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelum T.","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ula","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annemergmed.2024.12.002_bib1","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","article-title":"Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019","volume":"7","year":"2022","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1474-4422(18)30403-4","article-title":"Global, regional, and national burden of Alzheimer\u2019s disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib3","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.3390\/ijms24043754","article-title":"Alzheimer\u2019s disease: an updated overview of its genetics","volume":"24","author":"Andrade-Guerrero","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib4","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/alz.13016","article-title":"2023 Alzheimer\u2019s disease facts and figures","volume":"19","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib5","doi-asserted-by":"crossref","first-page":"1314.e1","DOI":"10.1016\/j.jamda.2022.05.024","article-title":"Optimal emergency department care practices for persons living with dementia: a scoping review","volume":"23","author":"Dresden","year":"2022","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib6","doi-asserted-by":"crossref","first-page":"1314.e31","DOI":"10.1016\/j.jamda.2022.03.019","article-title":"Detecting cognitive impairment and dementia in the emergency department: a scoping review","volume":"23","author":"Nowroozpoor","year":"2022","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib7","doi-asserted-by":"crossref","first-page":"1313.e15","DOI":"10.1016\/j.jamda.2022.02.024","article-title":"Emergency department communication in persons living with dementia and care partners: a scoping review","volume":"23","author":"Carpenter","year":"2022","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914499","article-title":"Anti-amyloid therapies for Alzheimer\u2019s disease and the amyloid cascade hypothesis","volume":"24","author":"Fedele","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib9","article-title":"Aduhelm: biogen abandons Alzheimer\u2019s drug after controversial approval left it unfunded by Medicare","volume":"384","author":"Dyer","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib10","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000208096","article-title":"Identifying genetic risk for amyloid-related imaging abnormalities","volume":"102","author":"Hardy","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib12","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib13","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","article-title":"A plaque-specific antibody clears existing \u03b2-amyloid plaques in Alzheimer\u2019s disease mice","volume":"76","author":"Demattos","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib14","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3390\/biom13030453","article-title":"The amyloid cascade hypothesis in Alzheimer\u2019s disease: should we change our thinking?","volume":"13","author":"Kurkinen","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","article-title":"Lecanemab, aducanumab, and gantenerumab - binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer\u2019s disease","volume":"20","author":"S\u00f6derberg","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","article-title":"Anti-amyloid monoclonal antibodies for the treatment of Alzheimer\u2019s disease","volume":"38","author":"Cummings","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","article-title":"A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer disease","volume":"15","author":"Panza","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.14283\/jpad.2024.37","article-title":"Alzheimer Europe Board. Anti-amyloid therapies for Alzheimer\u2019s disease: an Alzheimer Europe position paper and call to action","volume":"11","author":"Bradshaw","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib19","article-title":"Lecanemab blocks the effects of the A\u03b2\/fibrinogen complex on blood clots and synapse toxicity in organotypic culture","author":"Singh","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib21","doi-asserted-by":"crossref","first-page":"943","DOI":"10.17219\/acem\/171379","article-title":"Lecanemab (Leqembi) is not the right drug for patients with Alzheimer\u2019s disease","volume":"32","author":"Kurkinen","year":"2023","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib23","article-title":"Meaningful benefit and minimal clinically important difference (MCID) in Alzheimer\u2019s disease: open peer commentary","volume":"9","author":"Cummings","year":"2023","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/jnnp-2023-331941","article-title":"Comparison of relative change with effect size metrics in Alzheimer\u2019s disease clinical trials","volume":"95","author":"Goldberg","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib25","article-title":"Integrated Alzheimer\u2019s disease rating scale: clinically meaningful change estimates","volume":"8","author":"Wessels","year":"2022","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib26","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1093\/brain\/awad188","article-title":"Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics","volume":"146","author":"Hampel","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","article-title":"Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways","volume":"16","author":"Greenberg","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib28","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3233\/JAD-160216","article-title":"Central review of amyloid-related imaging abnormalities in two phase iii clinical trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease patients","volume":"57","author":"Ketter","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","article-title":"Amyloid-related imaging abnormalities (ARIA) in Alzheimer\u2019s disease patients treated with bapineuzumab: a retrospective analysis","volume":"11","author":"Sperling","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib30","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1073\/pnas.0600549103","article-title":"Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer\u2019s disease","volume":"103","author":"Mahley","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41583-023-00776-9","article-title":"Cell type-specific roles of APOE4 in Alzheimer disease","volume":"25","author":"Blumenfeld","year":"2024","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib32","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1001\/jamaneurol.2021.5205","article-title":"Amyloid-related imaging abnormalities and \u03b2-amyloid-targeting antibodies: a systematic review","volume":"79","author":"Filippi","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib33","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.3174\/ajnr.A3500","article-title":"MR imaging features of amyloid-related imaging abnormalities","volume":"34","author":"Barakos","year":"2013","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib34","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/alz.12366","article-title":"Prevalence of cerebral amyloid angiopathy: a systematic review and meta-analysis","volume":"18","author":"J\u00e4kel","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib35","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3390\/jcm13051245","article-title":"The impact of anti-amyloid immunotherapies on stroke care","volume":"13","author":"Bilodeau","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib37","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.55800","article-title":"Artificial intelligence assistive software tool for automated detection and quantification of amyloid-related imaging abnormalities","volume":"7","author":"Sima","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib38","doi-asserted-by":"crossref","first-page":"8220","DOI":"10.1038\/s41467-023-43933-5","article-title":"Fatal iatrogenic cerebral \u03b2-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer\u2019s disease","volume":"14","author":"Solopova","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib39","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJMc2215148","article-title":"Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke","volume":"388","author":"Reish","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib40","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","article-title":"Updated safety results from phase 3 lecanemab study in early Alzheimer\u2019s disease","volume":"16","author":"Honig","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib41","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1056\/NEJMc2215907","article-title":"Response to: multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke","volume":"388","author":"Sabbagh","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib43","doi-asserted-by":"crossref","DOI":"10.1111\/jgs.19099","article-title":"Challenges for emergency departments: anti-amyloid therapy and amyloid-related imaging abnormalities in persons with dementia","author":"Lo","year":"2024","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2023.120637","article-title":"Restricted access in the emergency department prevents MRI from being the workhorse for ischemic stroke care","volume":"448","author":"Kumar","year":"2023","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib45","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/ejhpharm-2021-003071","article-title":"Medication reconciliation\u2014is it possible to speed up without compromising quality? A before\u2013after study in the emergency department","volume":"30","author":"Hermann","year":"2023","journal-title":"Eur J Hosp Pharm"},{"key":"10.1016\/j.annemergmed.2024.12.002_bib46","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1016\/S0140-6736(19)30840-2","article-title":"Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial","volume":"393","author":"Salman","year":"2019","journal-title":"Lancet"}],"container-title":["Annals of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019606442401254X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019606442401254X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T13:28:31Z","timestamp":1762262911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019606442401254X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S019606442401254X"],"URL":"https:\/\/doi.org\/10.1016\/j.annemergmed.2024.12.002","relation":{},"ISSN":["0196-0644"],"issn-type":[{"value":"0196-0644","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-Amyloid Therapies for Alzheimer\u2019s Disease and Amyloid-Related Imaging Abnormalities: Implications for the Emergency Medicine Clinician","name":"articletitle","label":"Article Title"},{"value":"Annals of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annemergmed.2024.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American College of Emergency Physicians.","name":"copyright","label":"Copyright"}]}}